Spyre is developing next-generation antibodies that are engineered for prolonged activity in the body and formulated for delivery as monotherapies or combination therapies. Our innovative approach enables the exploration of treatment options with the potential to deliver uncompromising efficacy and convenience.
Our pipeline of novel antibodies target validated mechanisms with the potential to treat several gastrointestinal and rheumatological conditions.